Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Lymphoma 1Histiocytic Sarcoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 8pembrolizumab 6Filgrastim 5Busulfan 5fludarabine phosphate 4fludarabine 4Nivolumab 4Flow Cytometry 4Antilymphocyte Serum 4Alemtuzumab 4Tacrolimus 3Stem Cell Transplantation 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Mycophenolic Acid 3Melphalan 3Dexamethasone 3Carboplatin 3Biopsy 3Azacitidine 3valspodar 2atezolizumab 2aldesleukin 2X-Rays 2Vorinostat 2Vincristine 2Thiotepa 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × selpercatinib × Genitourinary × Clear all
NCT04320888 2026-05-27

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1 enrolled 3 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡